European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases A Major Setback for Amgen: Bemarituzumab's Gastric Cancer Ambitions Dim as Final Data Fails to Impress Sanofi Stock Plunges as Zantac Lawsuit Risks Re-Emerge Following Key Judicial Ruling